These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15858011)

  • 21. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A DNA vaccine coding for gB and gD of pseudorabies virus (suid herpes type 1) primes the immune system in the presence of maternal immunity more efficiently than conventional vaccines.
    van Rooij EM; Moonen-Leusen HW; de Visser YE; Middel WG; Boersma WJ; Bianchi AT
    Vaccine; 2006 Feb; 24(9):1264-73. PubMed ID: 16289276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.
    Naranjo-Gomez M; Lambour J; Piechaczyk M; Pelegrin M
    JCI Insight; 2018 May; 3(9):. PubMed ID: 29720574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic interactions of antibodies in rate of virus neutralization.
    Sanna PP; Ramiro-Ibañez F; De Logu A
    Virology; 2000 May; 270(2):386-96. PubMed ID: 10792998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
    Pelegrin M; Naranjo-Gomez M; Piechaczyk M
    Trends Microbiol; 2015 Oct; 23(10):653-665. PubMed ID: 26433697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells.
    Pelegrin M; Marin M; Noël D; Del Rio M; Saller R; Stange J; Mitzner S; Günzburg WH; Piechaczyk M
    Gene Ther; 1998 Jun; 5(6):828-34. PubMed ID: 9747463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies.
    Pelegrin M; Marin M; Oates A; Noël D; Saller R; Salmons B; Piechaczyk M
    Hum Gene Ther; 2000 Jul; 11(10):1407-15. PubMed ID: 10910138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of antiviral antibody response in koalas infected with koala retroviruses (KoRV).
    Fiebig U; Keller M; Möller A; Timms P; Denner J
    Virus Res; 2015 Feb; 198():30-4. PubMed ID: 25596496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retroviruses and autoimmune diseases.
    Matano T
    Jpn J Infect Dis; 1999 Jun; 52(3):106-9. PubMed ID: 10507988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.
    Lambour J; Naranjo-Gomez M; Piechaczyk M; Pelegrin M
    Emerg Microbes Infect; 2016 Aug; 5(8):e92. PubMed ID: 27530750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Stimulation of immunoreactivity against endogenous retroviruses and protection against leukemia in aged AKR mice after vaccination with antibodies to viral surface components. The role of antibodies to p15(E)].
    Schwarz H; Thiel HJ; Weinhold KJ; Bolognesi DP; Schäfer W
    Z Naturforsch C Biosci; 1984; 39(11-12):1199-202. PubMed ID: 6531950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-mediated immune control of a retrovirus does not require the microbiota.
    Wilks J; Beilinson H; Theriault B; Chervonsky A; Golovkina T
    J Virol; 2014 Jun; 88(11):6524-7. PubMed ID: 24648456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.
    Sautto G; Mancini N; Gorini G; Clementi M; Burioni R
    Biomed Res Int; 2013; 2013():838491. PubMed ID: 24058915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibody therapy and viral infections: update and beyond.
    Antonelli G
    Clin Microbiol Infect; 2011 Dec; 17(12):1757-8. PubMed ID: 22010631
    [No Abstract]   [Full Text] [Related]  

  • 35. The growth and potential of human antiviral monoclonal antibody therapeutics.
    Marasco WA; Sui J
    Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myocarditis.
    Kingman A; Van Bakel AB
    J S C Med Assoc; 2001 Oct; 97(10):421-3. PubMed ID: 11688311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Back to the future: antibody-based strategies for the treatment of infectious diseases.
    Oral HB; Ozakin C; Akdiş CA
    Mol Biotechnol; 2002 Jul; 21(3):225-39. PubMed ID: 12102547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses.
    Pelegrin M; Marsile-Medun S; Abba-Moussa D; Souchard M; Naranjo-Gomez M
    Antibodies (Basel); 2022 Jul; 11(3):. PubMed ID: 35892710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythrocytes as carriers of reduced glutathione (GSH) in the treatment of retroviral infections.
    Fraternale A; Casabianca A; Rossi L; Chiarantini L; Schiavano GF; Palamara AT; Garaci E; Magnani M
    J Antimicrob Chemother; 2003 Oct; 52(4):551-4. PubMed ID: 12972455
    [No Abstract]   [Full Text] [Related]  

  • 40. Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates.
    Spouge JL
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7581-5. PubMed ID: 1323844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.